LYELL IMMUNOPHARMA INC's ticker is LYEL and the CUSIP is 55083R104. A total of 80 filers reported holding LYELL IMMUNOPHARMA INC in Q1 2022. The put-call ratio across all filers is 0.02 and the average weighting 1.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $19,427,532 | -34.9% | 13,398,298 | +0.1% | 0.00% | -100.0% |
| Q1 2024 | $29,856,188 | +13.1% | 13,388,425 | -1.6% | 0.00% | 0.0% |
| Q4 2023 | $26,391,812 | +6.2% | 13,604,027 | -19.5% | 0.00% | 0.0% |
| Q3 2023 | $24,857,288 | -53.7% | 16,909,720 | +0.2% | 0.00% | 0.0% |
| Q2 2023 | $53,669,665 | +78.2% | 16,877,253 | +32.3% | 0.00% | 0.0% |
| Q1 2023 | $30,111,530 | -31.1% | 12,759,123 | +1.3% | 0.00% | 0.0% |
| Q4 2022 | $43,691,569 | -52.0% | 12,591,230 | +1.5% | 0.00% | -66.7% |
| Q3 2022 | $90,940,000 | +31.2% | 12,406,613 | +16.7% | 0.00% | +50.0% |
| Q2 2022 | $69,307,000 | +56.3% | 10,629,996 | +21.1% | 0.00% | +100.0% |
| Q1 2022 | $44,332,000 | +167.3% | 8,778,702 | +309.6% | 0.00% | – |
| Q4 2021 | $16,588,000 | -49.3% | 2,143,088 | -3.2% | 0.00% | -100.0% |
| Q3 2021 | $32,749,000 | +15.3% | 2,212,819 | +26.5% | 0.00% | 0.0% |
| Q2 2021 | $28,410,000 | – | 1,749,378 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| WuXi AppTec Co., Ltd. | 7,682,156 | $11,139,126 | 47.74% |
| MWG Management Ltd. | 20,162,332 | $29,235,381 | 31.93% |
| Orland Properties Ltd | 15,093,969 | $21,886,255 | 16.63% |
| Foresite Capital Management IV, LLC | 8,325,000 | $12,071,250 | 8.11% |
| Opaleye Management Inc. | 1,670,000 | $2,421,500 | 0.55% |
| MIC Capital Management UK LLP | 1,740,569 | $2,523,825 | 0.55% |
| Alphabet Inc. | 5,865,125 | $8,504,431 | 0.43% |
| HSG Holding Ltd | 3,045,997 | $4,995,435 | 0.18% |
| Orbimed Advisors | 6,405,098 | $9,287,392 | 0.18% |
| Ikarian Capital, LLC | 526,066 | $762,796 | 0.13% |